HIVEHIVE Digital Technologies Ltd.
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$0.15Beat
- vs −$0.16 expected on Nov 9
- Price
- $1.75
- +2.03% today · $825M cap
Past and upcoming reports
2
| Nov 9, 2026 | Sep 30, 2026 | After the market closes | −$0.16 | Beat−$0.15 | |
| Jun 24, 2026 | Mar 31, 2026 | Time not given | −$0.22 | not recorded | −18.14%2d |
After the report
Nov 9, 2026 report
HIVE missed EPS estimates as shares recovered 2.03%, while forward profitability remains unconfirmed
HIVE reported September-quarter EPS of -$0.15 versus -$0.10 estimated, a 47.4% miss. Shares rose 2.03% to $1.755 on November 11, but remained below the 20-, 50-, and 200-day averages. No company guidance or post-earnings news was provided. the main forward risks are continued losses, funding needs, and dilution.
Reported against expected
MissedReported EPS was -$0.15 for the quarter ended September 30, versus -$0.10 estimated. EPS missed by 47.4%.
Guidance
Company guidance was not provided in the payload. forward EPS growth estimates were 34.1% to 68.59%, but remain unverified by management guidance.
How the stock reacted
The event-day and subsequent reaction-window percentages were unavailable. HIVE rose 2.03% to $1.755 on November 11, with 10.0 million shares traded.
What changed
HIVE reported -$0.15 EPS, missing the -$0.10 estimate by 47.4%.
What the price now assumes
The 2.03% share gain contrasts with a 62.12% one-year decline and price below all listed moving averages.
What it means for the business
Maintain a cautious bias. upgrade only if losses narrow from -$0.15 and dilution risk remains contained.
The next one to three months, as we saw it then
Better case25%
Forward growth expectations begin translating into improving profitability, allowing the EPS miss to be treated as temporary.
Base case45%
The stock remains volatile while investors weigh rapid reported revenue growth against negative earnings and weak operating quality.
Worse case30%
Negative earnings persist and financing requirements or dilution reinforce the market’s existing skepticism.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.